Targeting APRIL in the treatment of glomerular diseases.
| Autor: | Cheung CK; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester National Health Service Trust, Leicester, UK., Barratt J; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester National Health Service Trust, Leicester, UK., Lafayette R; Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford University, Stanford, California, USA., Liew A; The Kidney and Transplant Practice, Mount Elizabeth Novena Hospital, Singapore., Suzuki Y; Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan., Tesař V; Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic., Trimarchi H; Nephrology Service and Kidney Transplant Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina., Wong MG; Department of Renal Medicine, Concord Repatriation General Hospital, Concord, Australia; Department of Medicine, University of Sydney, Camperdown, Australia., Zhang H; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, People's Republic of China., Rizk DV; Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Electronic address: drizk@uabmc.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Kidney international [Kidney Int] 2024 Nov; Vol. 106 (5), pp. 806-818. Date of Electronic Publication: 2024 Sep 07. |
| DOI: | 10.1016/j.kint.2024.08.012 |
| Abstrakt: | A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell-depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage. (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|